GENE ONLINE|News &
Innovent Announces Gastric Cancer Trial Win for Tyvyt, Reveals Plans for Another China Approval
Earlier today, Innovent announced positive outcomes from a gastric cancer trial that evaluated Tyvyt (sintilimab injection) in combination with chemotherapy. Interim analysis shows that the combo therapy met the primary endpoint of overall survival in patients.
Approved originally for treating relapsed or refractory classical Hodgkin’s lymphoma in China, Tyvyt had recently bagged its third NMPA approval. The immunotherapy, a fully human IgG4 anti-PD-1 monoclonal antibody, was developed by Innovent in collaboration with Eli Lilly.
Approved originally for treating relapsed or refractory classical Hodgkin’s lymphoma in China, Tyvyt had recently bagged its third NMPA approval. The immunotherapy, a fully human IgG4 anti-PD-1 monoclonal antibody, was developed by Innovent in collaboration with Eli Lilly.
GO Prime with only $1.49 now
LATEST
Bayer’s NUBEQA: Breakthrough in Prostate Cancer with 46% Risk Reduction and Future FDA Expansion Plans
2024-09-19
Five Biotech Stocks Soar: Eyes on Halozyme, United Therapeutics, Harmony, Ligand, and ADMA
2024-09-19
